SMYD5

Across TCGA pan-cancer cohorts, SMYD5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SMYD5 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SMYD5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMYD5 expression acts as an unfavorable survival marker, although some lineages such as OV and GBM show a favorable association.

CCRCC, OV, and HNSC are the cancer types where SMYD5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.613	0.940	<.001	45	view →
OV	DFS	Tertile	All	1.000	0.535	.045	16	view →
HNSC	OS	Tertile	All	0.266	1.000	.014	13	view →
COAD	DFS	Median	IV	0.493	0.944	.031	12	view →
UCEC	DFS	Median	All	0.934	1.000	.018	4	view →
GBM	OS	Median	All	0.651	0.416	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SMYD5–CCRCC (DFS)

Open the CCRCC breakdown →